Capricor Therapeutics (NASDAQ:CAPR) Shares Up 5.6% – What’s Next?

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) traded up 5.6% during trading on Monday . The stock traded as high as $13.80 and last traded at $13.80. 460,344 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 1,196,887 shares. The stock had previously closed at $13.07.

Analyst Ratings Changes

CAPR has been the subject of a number of recent analyst reports. Cantor Fitzgerald upped their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Maxim Group lifted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Down 0.8 %

The stock has a 50 day moving average price of $17.68 and a 200 day moving average price of $10.46. The stock has a market capitalization of $637.03 million, a price-to-earnings ratio of -13.22 and a beta of 3.98.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently modified their holdings of the business. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $133,000. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics during the second quarter worth $147,000. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics during the third quarter worth $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics in the third quarter valued at $192,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.